Companies /Healthcare

Fennec Pharmaceuticals Inc

NASDAQ: FENC Biotechnology
$10.96
▼ $0.34 (−3.01%) today
Markets closed · 5:06pm ET
Today · % change

Fundamentals

Market Cap
$408.5M
Profit Margin
-5.5%
Revenue (TTM)
$59.2M
EPS (TTM)
$-0.11
52-Week Range
$6 – $13
Street Target
$17.67

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., originally known as Adherex Technologies Inc. until 2014, is a biopharmaceutical company focused on addressing a specific healthcare challenge in pediatric cancer treatment. It develops PEDMARK, a unique formulation aimed at preventing hearing loss caused by platinum-based chemotherapy in children with cancer. Based in Research Triangle Park, North Carolina, since its inception in 1996, Fennec makes its innovative treatments available through specialized pediatric oncology networks.

FENC Coverage